April 2020’s molecule, the Mirati KRAS G12C inhibitor MRTX849, has been a hotly followed compound in development as it is the closest clinical KRAS inhibitor to the likely soon-to-be approved…
Home > MRTX849
this content is exclusive to
Premium members
Unlock this content with a Premium membership to read it now.